Short communicationPublished 10 Mar 2021
Commentary on Efficacy and Safety of Trabectedin in Metastatic Uterine Leiomyosarcoma: A Retrospective Multicenter Study of the Spanish Ovarian Cancer Research Group (GEICO)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Uterine Leiomyosarcoma (uLMS) is a very rare and aggressive carcinoma which, at advanced or recurrent stage, has a median overall survival of below 12 months. The Spanish ovarian cancer research group (GEICO), carried out a retrospective, observational, multicenter study involving 36 adult patients with unrespectable advanced or metastatic uLMS who received trabectedin after an anthracycline-containing regimen. The efficacy and safety observations found with trabectedin in this study were in line with previously shown in clinical trials. Trabectedin provides long-term carcinoma stabilization and adequate tolerability, thus it represents an appropriate option for the treatment of advanced uLMS. Beneficial effects are optimized when administered as second-line, after the failure of the anthracycline-containing regimen, which allows achieving longer clinical benefit and disease control. Furthermore, it is recommended to maintain the treatment with trabectedin until disease progression due to its better efficacy outcomes as well as its safety profile, allowing the long-term administration with no cumulative toxicities. Trabectedin has also demonstrated activity in diverse soft tissue sarcoma subtypes.
Subjects
Paediatrics & NeonatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinics in Mother and Child Health
- SubjectPaediatrics & Neonatology
- BylineArticles whose byline prints “Maria Jesus Rubio”
